INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial conducted across Europe, ...

T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.

Join us for Open Doors — as we approach the start of a new year, what trends will be impacting the biotech industry in 2025? And how can biotech executives, communications and marketing officers get ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Forbes contributors publish independent expert analyses and insights. Jim Osman is a finance expert with over 30 years of experience. As an investor, my greatest returns have usually come from areas ...

Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today announced approval to initiate a Phase I ...

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of ...

The real drug development delay? Bad communication.

The Pennsylvania Biotechnology Center in Doylestown has weathered nearly two decades of life sciences growth, but a ...